Market Research Logo

Artificial Intelligence for Hospital Cancer Immunotherapy: Market Shares, Strategies, and Forecasts, Worldwide, 2017 to 2023

Artificial Intelligence for Hospital Cancer Immunotherapy: Market Shares, Strategies, and Forecasts, Worldwide, 2017 to 2023

WinterGreen Research announces that it has published a new study Artificial Intelligence for Hospital Cancer Immunotherapy: Market Shares, Strategy, and Forecasts, Worldwide, 2017 to 2023. The 2017 study has 124 pages, 50 tables and figures. Worldwide markets are poised to achieve continuing growth as the artificial intelligence software increases diagnostic excellence, saving lives and lowering care delivery costs.

Hospital Artificial Intelligence for Immunotherapy drives sales of analytics systems.

Automated cancer immunotherapies from IBM Watson are implemented with artificial intelligence that looks at patient samples to detect the genetic characteristics of the cancer and isolate the immune particularities of the patient. Systems are able to take a multi-disciplinary integrated approach to looking at imaging and scans. The analysis of patient records, looking for effectiveness of particular treatments is more work than a human can do, the quantity of data is too high, so the artificial intelligence is being used to do that.

Personalized medicine is driving this market opportunity.

Systems are making a significant difference in saving lives.

Memorial Sloan Kettering physician-scientists are among leaders in the field developing groundbreaking immune therapies that are helping to treat several forms of advanced cancer that were previously untreatable. These scientists have played a lead role in developing and testing the immunotherapy drugs known as checkpoint inhibitors that “release the brakes” on the immune system.

Hospital care management can leverage artificial intelligence. Artificial intelligence is useful for providing highly tailored insights about individual patients for the purpose of personalizing immunotherapy care delivery. Artificial intelligence is useful for helping providers effectively address healthcare delivery because it details genetic specificity regarding individual patients.


1. CANCER IMMUNOTHERAPY ARTIFICIAL INTELLIGENCE MARKET DESCRIPTION AND MARKET DYNAMICS:
1.1 Artificial Intelligence Very Big Breakthrough in Cancer Immunotherapy
1.2 Ability of AI Solutions To Discover Schemas in Large Databases
2. CANCER IMMUNOTHERAPEUTIC ARTIFICIAL INTELLIGENCE (AI) MARKET DRIVING FORCES
2.1 Cancer Immunotherapeutic Artificial Intelligence (AI) Market Driving Forces
2.2 Artificial Intelligence Oncology Treatment Market Shares:
2.3 Cancer Immunotherapy Artificial Intelligence for Hospitals Market Forecasts:
2.4 Worldwide Checkpoint Inhibitor and Oncology Treatment Market Forecasts
2.5 Cancer Statistics
2.5.1 Cancer Among The Leading Causes Of Death Worldwide
2.6 Hospital Artificial Intelligence (AI) Challenges
2.7 Hospital Artificial Intelligence Software Prices:
2.8 Hospital Artificial Intelligence Regional Segments:
3. CANCER IMMUNOTHERAPY HOSPITAL ARTIFICIAL INTELLIGENCE PRODUCTS:
3.1 Memorial Sloan Kettering
3.1.1 Memorial Sloan Kettering Parker Institute
3.1.2 CAR T Immunotherapy
3.1.2 T-Cell Therapies from Merck and Bristol-Myers Squibb
3.1.3 Memorial Sloan Kettering Cancer Diagnostic Test, MSK-IMPACT
3.1.4 Memorial Sloan Kettering Intensified Tumor Testing
3.1.5 Memorial Sloan Kettering Effective Sequencing
3.1.6 Memorial Sloan Kettering Actionable the most important cancer geneTargets
3.2 MD Anderson Immune Therapy
3.2.1 MD Anderson Immune Therapy
3.2.2 MD Anderson Personalized Therapy TNBC Cancer Trials
3.3 Partners Dana Farber Immunotherapy
3.3.1 Advanced Melanoma Has Been The Test Case For The Study Of Immune Checkpoint-Inhibiting Therapy
3.4 Partners HealthCare, IBM, and GE Healthcare
3.5 IBM Watson
3.5.1 IBM Genomic And Immunotherapy Supercomputing for Patient Management
3.5.2 Mayo Clinic and IBM Watson
3.6 Google’s AI Subsidiary DeepMind is Partnering With Another UK hospital
3.7 Prognos
4. HOSPITAL ARTIFICIAL INTELLIGENCE RESEARCH AND TECHNOLOGY:
4.1 IBM AI Research
4.1.1 Neural Representation of Sketch Drawings
4.1.2 IBM Watson Health And Broad Institute Launch Major Research Initiative To Study Why Cancers Become Drug Resistant
4.1.3 IBM and Quest Diagnostics
4.2 Research at Google
4.3 Google and Nvidia Artificial Intelligence
5. HOSPITAL ARTIFICIAL INTELLIGENCE COMPANIES
5.1 Alphabet / Google
5.1.1 Google Artificial Intelligence Subsidiary DeepMind Healthcare Initiative
5.2 Broad Institute of MIT and Harvard
5.3 Foundation Medicine
>120k
>30
>200
5.3.1 Foundation Medicine
5.4 General Electric (GE)
5.4.1 General Electric Revenue by Segment
5.4.2 GE Healthcare and Massachusetts General Artificial Intelligence
5.5 Gritstone Oncology
5.6 IBM 94
5.6.1 IBM Watson Health
5.6.2 IBM Active in BWH, MGH Partnership To Advance Artificial Intelligence In Health Care
5.6.3 IBM Watson Artificial Intelligence for Oncology
5.6.4 IBM Watson Genomics by Quest Diagnostics
5.6.5 IBM Watson Healthcare Revenue
5.6.6 IBM Watson Solutions Software Healthcare Revenue
5.7 Juno Therapeutics
5.7.1 Juno Therapeutics Power Of Individualized Cancer Treatment
5.7.2 Juno Therapeutics CAR and TCR Technologies
5.8 Myriad Genetics
5.9 Nvidia
5.9.1 NVIDIA
5.9.2 Nvidia Revenue
5.7.3 Nvidia Customer HeartFlow Medical Technology
5.10 Pfizer
5.11 Prognos
5.11.1 Coding Healthcare Datasets Full Of Unstructured Text
5.12 Quest Diagnostics
5.12.1 IBM Personalized Healthcare: Watson Genomics from Quest Diagnostics
5.12.2 Quest Diagnostics Revenue
5.13 Safeguard Scientifics Announces Second Quarter 2017 Financial Results
5.13.1 Safeguard Scientifics Prognos DxCloud
WINTERGREEN RESEARCH,
WinterGreen Research Methodology
WinterGreen Research Process
Market Research Study
WinterGreen Research Global Market Intelligence Company
Report Description: Hospital Artificial Intelligence Models Matter
List Of Figures
Abstract: Artificial Intelligence Applied to Cancer Immunotherapy Vastly Improves Treatments and Outcomes
Figure 1. T Lymphocycte
Figure 2. Cancer Immunotherapeutic Artificial Intelligence (AI) Market Driving Forces
Figure 3. Healthcare Safety Features Implemented by Artificial Intelligence (AI)
Figure 4. Cancer Immunotherapy Artificial Intelligence Market Shares, Systems, Dollars, Worldwide, 2016
Figure 5. Cancer Immunotherapy Hospital Artificial Intelligence Market Shipments Forecasts Dollars, Worldwide, 2017-2023 0
Figure 6. Cancer Artificial Intelligence Components
Figure 7. Hospital Artificial Intelligence Predictive Functions
Figure 8. Cancer Immunotherapeutic Artificial Intelligence (AI) Market Driving Forces
Figure 9. Healthcare Safety Features Implemented by Artificial Intelligence (AI)
Figure 10. Cancer Immunotherapy Artificial Intelligence Market Shares, Systems, Dollars, Worldwide, 2016 8
Figure 11. Cancer Immunotherapy Artificial Intelligence Systems, Market Shares, Dollars, Worldwide, 2016
Figure 12. Cancer Immunotherapy Artificial Intelligence Market Shipments Forecasts Dollars, Worldwide, 2017-2023
Figure 13. Cancer Immunotherapy Artificial Intelligence Market Shipments Forecasts Dollars, Worldwide, 2017-2023
Figure 14. AI Replacements for Supervised Manual Techniques For Diagnosis And Care Delivery.
Figure 15. Hospital Artificial Intelligence Long-Term Goal
Figure 16. Hospital Artificial Intelligence Action Functions
Figure 17. Immuno-Oncology Market Applications
Figure 18. Key players in the immuno-oncology market
Figure 19. Estimated New Cancer Cases in the US in 2017
Figure 20. Trends in Cancer Incidence Rates, US, 1975 to 2013
Figure 21. Estimated Cancer Deaths in the US in 2017
Figure 22. Pancreatic Cancer Survival Rate
Figure 23. Trends in Cancer Death Rates Among Males, US 1930 to 2014
Figure 24. Hospital Artificial Intelligence (AI) Challenges
Figure 25. Hospital Artificial Intelligence (AI) Human Factors
Figure 26. IBM 8408 E8E PSeries AIX Power8 Server EPV4 24-Core
Figure 27. Cancer Immunotherapy Artificial Intelligence Systems, Regional Market Segments, 2016
Figure 28. Cancer Immunotherapy Artificial Intelligence Systems, Regional Market Segments, 2016
Figure 29. T Lymphocycte
Figure 30. MD Anderson Genetic Sequencing Services:
Figure 31. MD Anderson Sample quality check (DNA and RNA)
Figure 32. MD Anderson Cancer Immunotherapy Custom Services:
Figure 33. Partners Dana Farber Immunotherapy Directions
Figure 34. Stephen F. Hodi, MD, Director, Partners Dana Farber Melanoma Center; Director, Center for Immuno-Oncology
Figure 35. Truven Health Analytics Products
Figure 36. IBM TrueNorth Neurosynaptic System
Figure 37. AI Makes Words Manageable
Figure 38. Foundation Medicine Metrics
Figure 39. GE Healthcare and Massachusetts General Artificial Intelligence Healthcare Initiative Workflow
Figure 40. GE Healthcare and Massachusetts General Artificial Intelligence Healthcare Initiative Center of Excellence
Figure 41. Juno Therapeutics Immunotherapy
Figure 42. Chimeric Antigen Receptor (CAR) T cell Technology
Figure 43. T Cell Receptor (TCR) Technology
Figure 44. Tumor Cells’ Ability To Develop Resistance
Figure 45. NVIDIA Tesla V100 Accelerator
Figure 46. Nvidia Interconnect and Memory Parameters
Figure 47. Prognos Investors
Figure 48. Percent Patients with Abnormally High Test 5 years Prior to First Pancreatic Cancer Diagnosis Stratified by Test and by Year
Figure 49. Prognos Pancreatic Cancer Diagnosis Test Result Variance
Figure 50. Watson Genomics from Quest Diagnostics Features:

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report